proligestone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

proligestone: a synthetic progestational steroid; used to suppress ESTRUS [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	71906
CHEMBL ID	2106696
SCHEMBL ID	796537
MeSH ID	M0068628

Synonyms (27)

Synonym
proligestone
D08429
23873-85-0
proligestone (inn)
delvosteron [veterinary] (tn)
covinan [veterinary] (tn)
delvosteron
covinan
CHEMBL2106696
proligestona [inn-spanish]
einecs 245-922-6
proligestona
55772lj01v ,
proligestone [inn:ban]
proligestonum
14,17-dihydroxypregn-4-ene-3,20-dione, cyclic acetal with propionaldehyde
proligestonum [inn-latin]
unii-55772lj01v
SCHEMBL796537
proligestone [inn]
proligestone [mart.]
proligestone [mi]
J-015252
(1r,2r,10r,11s,14s,15r)-15-acetyl-17-ethyl-10,14-dimethyl-16,18-dioxapentacyclo[13.3.2.01,14.02,11.05,10]icos-5-en-7-one
Q907070
DTXSID501016687
S12326

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" Effects on cortisol persisted for two weeks after MA dosage ceased."	( Comparative effects of proligestone and megestrol acetate on basal plasma glucose concentrations and cortisol responses to exogenous adrenocorticotrophic hormone in cats. Church, DB; Emslie, DR; Middleton, DJ; Watson, AD, 1989)	0.59
" The cats given MA (n = 7) developed significant suppression of plasma ACTH concentrations and hyperinsulinaemia during treatment and for two to four weeks after MA dosage ceased."	( Effects of proligestone and megestrol on plasma adrenocorticotrophic hormone, insulin and insulin-like growth factor-1 concentrations in cats. Church, DB; Emslie, DR; Middleton, DJ; Tan, K; Watson, AD; Wong, D, 1994)	0.68

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (46.88)	18.7374
1990's	10 (31.25)	18.2507
2000's	6 (18.75)	29.6817
2010's	1 (3.13)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	42.68 (24.57)
Research Supply Index	3.56 (2.92)
Research Growth Index	4.22 (4.65)
Search Engine Demand Index	60.75 (26.88)
Search Engine Supply Index	1.96 (0.95)

This Compound (42.68)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (3.03%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	5 (15.15%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (81.82%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	1.97	1	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	6.97	1	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
sulfamethazine Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.	1.97	1	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic
medroxyprogesterone acetate [no description available]	3.37	7	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
chlormadinone acetate Chlormadinone Acetate: An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL).	2.01	1	corticosteroid hormone
medroxyprogesterone [no description available]	3.22	6	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
megestrol acetate [no description available]	7.38	2	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
megestrol Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.	2.38	2	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
zeranol Zeranol: A non-steroidal estrogen analog.	6.97	1	macrolide
aglepristone aglepristone: Alizine is tradename	2.01	1	oxo steroid
trelstar Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.	2.05	1
deslorelin deslorelin: Ovuplant is tradename for a short-term-release implant containing deslorelin acetate; RN given refers to D-isomer; RN for cpd without isomeric designation not avail 12/90	2.05	1	oligopeptide
delmadinone [no description available]	2.01	1

Condition	Relationship Strength	Studies	Trials
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	4.46	5	1
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	3.08	5	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.01	1	0
Canine Diseases [description not available]	3.58	9	0
Benign Neoplasms [description not available]	2.36	2	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.36	2	0
Complications, Labor [description not available]	1.96	1	0
Experimental Mammary Neoplasms [description not available]	1.98	1	0
Fibroadenoma An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)	1.98	1	0
Acute Liver Injury, Drug-Induced [description not available]	1.98	1	0
Liver Dysfunction [description not available]	1.98	1	0
Animal Mammary Carcinoma [description not available]	1.98	1	0
Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.	1.98	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.98	1	0
Liver Diseases Pathological processes of the LIVER.	1.98	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	1.98	1	0
Calcification, Pathologic [description not available]	2	1	0
Cancer of Skin [description not available]	2	1	0
Calcinosis Pathologic deposition of calcium salts in tissues.	7	1	0
Skin Neoplasms Tumors or cancer of the SKIN.	2	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.01	1	0
Inappropriate GH Secretion Syndrome (Acromegaly) [description not available]	2.01	1	0
Dwarfism, Growth Hormone Deficiency [description not available]	2.01	1	0
Atypical Endometrial Hyperplasia A benign form of endometrial hyperplasia with increased number of cells with atypia. The atypical cells are large and irregular and have an increased nuclear/cytoplasmic ratio. The risk of progression to endometrial carcinoma rises with the increasing degree of cell atypia.	2.01	1	0
Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)	2.01	1	0
Dwarfism, Pituitary A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development.	2.01	1	0
Endometrial Hyperplasia Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.	2.01	1	0
Endomyometritis Inflammation of both the ENDOMETRIUM and the MYOMETRIUM, usually caused by infections after a CESAREAN SECTION.	2.38	2	0
Dermatitis Any inflammation of the skin.	1.97	1	0
Endometritis Inflammation of the ENDOMETRIUM, usually caused by intrauterine infections. Endometritis is the most common cause of postpartum fever.	2.38	2	0
Allergy, Drug [description not available]	2.38	2	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	2.38	2	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.66	3	0
Allergic Reaction [description not available]	1.96	1	0
Insect Bites [description not available]	1.96	1	0
Ectoparasitic Infestations Infestations by PARASITES which live on, or burrow into, the surface of their host's EPIDERMIS. Most ectoparasites are ARTHROPODS.	1.96	1	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	1.96	1	0
Insect Bites and Stings Bites and stings inflicted by insects.	1.96	1	0

chemdatabank.com